-
1.发明申请COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS 有权用于治疗或预防肥胖和胰岛素抵抗障碍的组合物公开(公告)号：US20120029065A1
公开(公告)日：2012-02-02
申请号：US13192011
申请日：2011-07-27
Applicant: David A. Sinclair , Maria Alexander-Bridges
Inventor： David A. Sinclair , Maria Alexander-Bridges
CPC classification number: A61K31/455 , A61K31/00 , A61K31/05 , A61K31/12 , A61K31/353 , A61K31/7048 , A61K31/7052 , A61K31/706 , A61K45/06 , Y10S514/866 , Y10S514/909
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Abstract translation: 本文提供了用于调节沉默调节蛋白的活性或水平的方法和组合物，从而治疗或预防肥胖或胰岛素抵抗障碍，例如受试者中的糖尿病。 示例性方法包括使细胞与沉默调节蛋白的活化化合物或抑制化合物接触，从而分别增加或减少脂肪蓄积。
-
2.发明申请COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS 有权用于治疗或预防肥胖和胰岛素抵抗障碍的组合物公开(公告)号：US20100316679A1
公开(公告)日：2010-12-16
申请号：US12683998
申请日：2010-01-07
Applicant: David A. Sinclair , Maria Alexander-Bridges
Inventor： David A. Sinclair , Maria Alexander-Bridges
CPC classification number: A61K31/05 , A61K31/00 , A61K31/12 , A61K31/353
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Abstract translation: 本文提供了用于调节沉默调节蛋白的活性或水平的方法和组合物，从而治疗或预防肥胖或胰岛素抵抗障碍，例如受试者中的糖尿病。 示例性方法包括使细胞与沉默调节蛋白的活化化合物或抑制化合物接触，从而分别增加或减少脂肪蓄积。
-
公开(公告)号：US5496831A
公开(公告)日：1996-03-05
申请号：US242409
申请日：1994-05-13
Applicant: Maria C. Alexander-Bridges , Hui-Fen Zhao
Inventor： Maria C. Alexander-Bridges , Hui-Fen Zhao
IPC: A61K31/436 , A01N43/42
CPC classification number: A61K31/436
Abstract: The invention features methods of treating insulin-induced obesity, weight gain, and other conditions associated with hyperinsulinemia.
Abstract translation: 本发明的特征在于治疗胰岛素诱导的肥胖症，体重增加和与高胰岛素血症相关的其它病症的方法。
-
4.发明授权Methods of stimulating fat mobilization using a polymer conjugated polyphenol 有权使用聚合物缀合的多酚刺激脂肪动员的方法公开(公告)号：US09272049B2
公开(公告)日：2016-03-01
申请号：US13156047
申请日：2011-06-08
Applicant: Maria Alexander-Bridges , Shaker A. Mousa , Paul J. Davis
Inventor： Maria Alexander-Bridges , Shaker A. Mousa , Paul J. Davis
CPC classification number: G01N33/5023 , A61K47/58 , A61K47/593 , A61K47/60 , A61K47/61 , C12N15/1086
Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.
Abstract translation: 本文提供了通过靶向选择的细胞外和细胞外蛋白质的RGD结合位点来预防和治疗与代谢综合征相关的疾病和危险因素的组合物和方法。 典型的组合物包括通过酯键的RGD-多酚共轭物; 与RGD类似物或模拟物缀合的多酚聚合物; 和与多酚连接的RGD聚合物缀合物。
-
5.发明授权Method for reducing the weight of a subject or inhibiting weight gain in a subject 有权用于减轻受试者体重或抑制受试者体重增加的方法公开(公告)号：US08242171B2
公开(公告)日：2012-08-14
申请号：US12683998
申请日：2010-01-07
Applicant: David A. Sinclair , Maria Alexander-Bridges
Inventor： David A. Sinclair , Maria Alexander-Bridges
CPC classification number: A61K31/05 , A61K31/00 , A61K31/12 , A61K31/353
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Abstract translation: 本文提供了用于调节沉默调节蛋白的活性或水平的方法和组合物，从而治疗或预防肥胖或胰岛素抵抗障碍，例如受试者中的糖尿病。 示例性方法包括使细胞与沉默调节蛋白的活化化合物或抑制化合物接触，从而分别增加或减少脂肪蓄积。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20080312239A1
公开(公告)日：2008-12-18
申请号：US12138560
申请日：2008-06-13
Applicant: Robert L. Zerbe , Alexander Bridges , Risto Lammintausta , Rochelle Hanley , Stuart Dombey
Inventor： Robert L. Zerbe , Alexander Bridges , Risto Lammintausta , Rochelle Hanley , Stuart Dombey
IPC: A61K31/53 , A61K31/085 , A61K31/135 , A61P15/00 , A61K31/4985 , A61K31/496
CPC classification number: A61K31/085 , A61K9/00 , A61K31/075 , A61K31/135 , A61K31/496 , A61K31/4985 , A61K31/519 , A61K31/53
Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.
Abstract translation: 治疗勃起功能障碍（ED）的方法包括以有效提高受试者睾酮水平的量给予有需要的受试者的fispemifene的步骤。 在与常规ED治疗没有足够反应的个体中，可以将fispemifene与PDE-5抑制剂组合使用。 还公开了通过与PDE-5抑制剂组合施用克洛米芬，enclomifene，ospemifene，托瑞米芬及其混合物来治疗ED的方法。
-
公开(公告)号：US20050171163A1
公开(公告)日：2005-08-04
申请号：US10442917
申请日：2003-05-21
Applicant: Larry Bratton , Alexander Bridges , David Connor , Steven Miller , Yuntao Song , Kuai-Lin Sun , Bharat Trivedi , Paul Unangst
Inventor： Larry Bratton , Alexander Bridges , David Connor , Steven Miller , Yuntao Song , Kuai-Lin Sun , Bharat Trivedi , Paul Unangst
IPC: C07D233/64 , A61K31/10 , A61K31/121 , A61K31/167 , A61K31/22 , A61K31/341 , A61K31/381 , A61K31/4164 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/4402 , A61K31/4439 , A61P9/10 , A61P19/02 , A61P29/00 , A61P37/06 , A61P43/00 , C07C311/03 , C07C311/27 , C07C317/18 , C07C317/24 , C07C317/28 , C07C317/44 , C07C323/22 , C07D213/44 , C07D213/50 , C07D233/54 , C07D239/26 , C07D261/08 , C07D263/32 , C07D277/10 , C07D277/26 , C07D307/40 , C07D307/46 , C07D307/71 , C07D307/80 , C07D333/18 , C07D333/22 , C07D333/38 , C07D333/44 , C07D413/02 , C07D413/04
CPC classification number: C07C311/03 , C07C311/27 , C07C317/18 , C07C317/24 , C07C317/28 , C07C317/44 , C07D213/50 , C07D233/64 , C07D239/26 , C07D261/08 , C07D263/32 , C07D277/10 , C07D277/26 , C07D307/46 , C07D307/71 , C07D307/80 , C07D333/22 , C07D333/38 , C07D333/44 , C07D413/04
Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
Abstract translation: 本发明涉及可用于治疗趋化因子介导的病症的砜。 在某些实施方案中，本发明涉及作为MCP-1受体拮抗剂的化合物。
-
公开(公告)号：US5340833A
公开(公告)日：1994-08-23
申请号：US877664
申请日：1992-05-01
Applicant: Alexander Bridges , Bruce A. Littlefield , C. Eric Schwartz
Inventor： Alexander Bridges , Bruce A. Littlefield , C. Eric Schwartz
IPC: A61K31/38 , A61K31/381 , A61K31/44 , A61K31/4436 , A61P9/00 , A61P19/02 , A61P19/10 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D333/58 , C07D333/62 , C07D333/66 , C07D333/68 , C07D333/74 , C07D409/04 , C07D409/06 , C07D409/14 , C07D495/04
CPC classification number: C07D409/04 , C07D333/74 , C07D409/06 , C07D409/14 , C07D495/04
Abstract: Disclosed are benzothiophene and thienothiophene derivatives useful for inhibiting urokinase activity.
Abstract translation: 公开了可用于抑制尿激酶活性的苯并噻吩和噻吩并噻吩衍生物。
-
公开(公告)号：US08017634B2
公开(公告)日：2011-09-13
申请号：US11174000
申请日：2005-07-01
Applicant: David A. Sinclair , Maria Alexander-Bridges
Inventor： David A. Sinclair , Maria Alexander-Bridges
IPC: A61K31/44 , A61K31/35 , A61K31/155
CPC classification number: A61K31/455 , A61K31/00 , A61K31/05 , A61K31/12 , A61K31/353 , A61K31/7048 , A61K31/7052 , A61K31/706 , A61K45/06 , Y10S514/866 , Y10S514/909
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Abstract translation: 本文提供了用于调节沉默调节蛋白的活性或水平的方法和组合物，从而治疗或预防肥胖或胰岛素抵抗障碍，例如受试者中的糖尿病。 示例性方法包括使细胞与沉默调节蛋白的活化化合物或抑制化合物接触，从而分别增加或减少脂肪蓄积。
-
10.发明申请公开(公告)号：US20100261729A1
公开(公告)日：2010-10-14
申请号：US12795986
申请日：2010-06-08
Applicant: Robert L. Zerbe , Alexander Bridges , Risto Lammintausta , Rochelle Hanley , Stuart Dombey
Inventor： Robert L. Zerbe , Alexander Bridges , Risto Lammintausta , Rochelle Hanley , Stuart Dombey
IPC: A61K31/497 , A61P15/10
CPC classification number: A61K31/085 , A61K9/00 , A61K31/075 , A61K31/135 , A61K31/496 , A61K31/4985 , A61K31/519 , A61K31/53
Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.
Abstract translation: 治疗勃起功能障碍（ED）的方法包括以有效提高受试者睾酮水平的量给予有需要的受试者的fispemifene的步骤。 在与常规ED治疗没有足够反应的个体中，可以将fispemifene与PDE-5抑制剂组合使用。 还公开了通过与PDE-5抑制剂组合施用克洛米芬，enclomifene，ospemifene，托瑞米芬及其混合物来治疗ED的方法。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.03 seconds)
